In December 2003 the FDA approved Symbyax® to treat bipolar depression. Symbyax® is a combination of fluoxetine and olanzapine.
Side Effects
Common side effects include muscle-rigidity, muscle-stiffness, muscle-twitches, restlesness, sedation, and weight-gain. Olanzapine is reported to cause tardive dyskinesia and neurological malignant syndrome.
Olanzapine is manufactured by Eli Lilly (NYSE: LLY).